Kenvue Inc. (NYSE:KVUE) Shares Bought by Global X Japan Co. Ltd.

Global X Japan Co. Ltd. grew its holdings in Kenvue Inc. (NYSE:KVUE - Free Report) by 120.3% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 52,473 shares of the company's stock after buying an additional 28,651 shares during the quarter. Global X Japan Co. Ltd.'s holdings in Kenvue were worth $1,199,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Price T Rowe Associates Inc. MD increased its position in Kenvue by 3.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 245,885,918 shares of the company's stock worth $5,249,665,000 after buying an additional 8,211,748 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of Kenvue by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 218,543,705 shares of the company's stock worth $4,665,908,000 after purchasing an additional 1,636,741 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its stake in shares of Kenvue by 12.3% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 97,661,344 shares of the company's stock worth $2,085,070,000 after acquiring an additional 10,682,003 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Kenvue by 3.1% in the fourth quarter. Geode Capital Management LLC now owns 46,068,931 shares of the company's stock worth $980,989,000 after acquiring an additional 1,391,854 shares in the last quarter. Finally, Franklin Resources Inc. lifted its stake in shares of Kenvue by 61.5% in the fourth quarter. Franklin Resources Inc. now owns 42,719,377 shares of the company's stock worth $912,059,000 after acquiring an additional 16,269,721 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Kenvue Stock Performance

Shares of NYSE:KVUE traded up $0.03 during trading on Friday, hitting $21.39. 24,956,266 shares of the company traded hands, compared to its average volume of 16,450,432. The stock has a market capitalization of $41.03 billion, a price-to-earnings ratio of 38.88, a PEG ratio of 3.32 and a beta of 0.98. The business's fifty day moving average is $23.00 and its 200-day moving average is $22.43. Kenvue Inc. has a one year low of $17.67 and a one year high of $25.17. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.63.

Kenvue (NYSE:KVUE - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported $0.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.23 by $0.01. Kenvue had a return on equity of 20.87% and a net margin of 6.90%. The business had revenue of $3.74 billion during the quarter, compared to the consensus estimate of $3.69 billion. During the same period in the previous year, the firm posted $0.28 earnings per share. The business's revenue was down 3.9% on a year-over-year basis. As a group, equities analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, May 28th. Shareholders of record on Wednesday, May 14th were given a dividend of $0.205 per share. The ex-dividend date was Wednesday, May 14th. This represents a $0.82 dividend on an annualized basis and a yield of 3.83%. Kenvue's dividend payout ratio (DPR) is presently 149.09%.

Analyst Ratings Changes

Several research firms recently commented on KVUE. Canaccord Genuity Group boosted their price target on Kenvue from $24.00 to $29.00 and gave the stock a "buy" rating in a research note on Wednesday, March 5th. Redburn Atlantic initiated coverage on Kenvue in a report on Thursday, April 10th. They issued a "neutral" rating and a $23.50 price objective for the company. Barclays boosted their price objective on Kenvue from $22.00 to $23.00 and gave the company an "equal weight" rating in a report on Monday, May 12th. UBS Group boosted their price objective on Kenvue from $24.00 to $25.00 and gave the company a "neutral" rating in a report on Friday, May 9th. Finally, Evercore ISI initiated coverage on Kenvue in a report on Monday, March 24th. They issued an "in-line" rating and a $25.00 price objective for the company. Seven research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, Kenvue currently has a consensus rating of "Hold" and an average target price of $25.33.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.